{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T18:22:03Z","timestamp":1786818123457,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease characterized by a type I interferon (IFN)-driven interface dermatitis in which cytotoxic lymphocytes invade the basal layer of the epidermis and induce the keratinocytic cell death. Anifrolumab is a monoclonal antibody targeting the type I interferon receptor (IFNAR1) approved for the therapy of systemic lupus erythematosus (SLE). Recent clinical observations indicated that anifrolumab might be particularly effective in the treatment of lupus erythematosus (LE) skin manifestations. We hypothesize that anifrolumab does not only inhibit interferons circulating in the blood but also has a direct impact on keratinocytes. Our results show that IFNAR1 is expressed in lesional keratinocytes in CLE patients in immunohistochemistry. Gene expression analyses confirmed a strong activation of the interferon signaling pathway in CLE lesions. <jats:italic>In vitro<\/jats:italic> experiments with HaCaT cells, N\/TERT cells and normal epidermal human keratinocyte 3D-epidermis models demonstrated that anifrolumab inhibits the expression of CLE-typical IFN-mediated proteins, including MxA and CXCL10 expression after stimulation with IFN\u03b1 and synthetic and endogenous immunogenic nucleic acids. This study demonstrates that anifrolumab not only suppresses the type I IFN effect, but also inhibits other pathways of keratinocyte stimulation including pattern recognition receptor (PRR)-activation and chemokine signaling pathways, which are crucial player in the autoamplification of the proinflammatory vicious circle in CLE. These results suggest that the direct effect of anifrolumab on keratinocytes may be an important factor in its clinical efficacy in LE skin lesions and may explain the beneficial clinical effects of anifrolumab specifically in LE skin lesions.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1648001","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:27:53Z","timestamp":1760333273000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Anifrolumab has a direct immunoregulatory effect on inflamed keratinocytes: implications for the treatment of lupus erythematosus skin lesions"],"prefix":"10.3389","volume":"16","author":[{"given":"Ksenia","family":"Kalyniuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Fetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Gr\u00fctzbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugce","family":"Guel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalija","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00774-8","article-title":"Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions","volume":"24","author":"Niebel","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.96","article-title":"An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in \u201cinterface dermatitis","volume":"128","author":"Wenzel","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.915828","article-title":"Current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus","volume":"9","author":"Fetter","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs","year":"2018","journal-title":"Lupus Sci Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"10688","DOI":"10.1038\/s41467-024-54559-6","article-title":"Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases","volume":"15","author":"Seremet","year":"2024","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/path.1721","article-title":"Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus","volume":"205","author":"Wenzel","year":"2005","journal-title":"J Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13253","article-title":"JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus","volume":"26","author":"Klaeschen","year":"2017","journal-title":"Exp Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622511","article-title":"Immunostimulatory endogenous nucleic acids perpetuate interface dermatitis-translation of pathogenic fundamentals into an in vitro model","volume":"11","author":"Braegelmann","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241273023","article-title":"Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients","volume":"33","author":"Flouda","year":"2024","journal-title":"Lupus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 Receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2752","article-title":"Taming lupus-a new understanding of pathogenesis is leading to clinical advances","volume":"18","author":"Liu","year":"2012","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000761","article-title":"Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials","volume":"10","author":"Bruce","year":"2023","journal-title":"Lupus Sci Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221425","article-title":"Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials","volume":"81","author":"Vital","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.41598","article-title":"Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study","volume":"73","author":"Chatham","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxae018","article-title":"Efficacy of anifrolumab in long-term intractable alopecia due to discoid lupus erythematosus","volume":"8","author":"Azuma","year":"2024","journal-title":"Mod Rheumatol Case Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-024-01168-3","article-title":"Keratinocytes - amplifiers of immune responses in systemic lupus erythematosus","volume":"27","author":"Klein","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213197","article-title":"Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa","volume":"77","author":"Sarkar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7435621","DOI":"10.1155\/2017\/7435621","article-title":"HaCaT cells as a reliable in vitro differentiation model to dissect the inflammatory\/repair response of human keratinocytes","volume":"2017","author":"Colombo","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2012.20.2.171","article-title":"HaCaT keratinocytes and primary epidermal keratinocytes have different transcriptional profiles of cornified envelope-associated genes to T helper cell cytokines","volume":"20","author":"Seo","year":"2012","journal-title":"Biomol Ther (Seoul)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11838","DOI":"10.1038\/s41598-017-12041-y","article-title":"Immortalized N\/TERT keratinocytes as an alternative cell source in 3D human epidermal models","volume":"7","author":"Smits","year":"2017","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123449","article-title":"Rapid response of refractory systemic lupus erythematosus skin manifestations to anifrolumab-A case-based review of clinical trial data suggesting a domain-based therapeutic approach","volume":"11","author":"Pl\u00fc\u00df","year":"2022","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39553","article-title":"Role of anifrolumab in refractory cutaneous manifestations of lupus erythematosus: A case series and literature review","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","first-page":"105064","DOI":"10.1016\/j.archoralbio.2021.105064","article-title":"The expression of membrane-bound complement regulatory proteins CD46, CD55 and CD59 in oral lichen planus","volume":"124","author":"Li","year":"2021","journal-title":"Arch Oral Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.42392","article-title":"A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1648001\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:28:00Z","timestamp":1760333280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1648001\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1648001"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1648001","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"article-number":"1648001"}}